Neprilysin 2 catalyses the degradation of natriuretic peptides despite sacubitrilat Inhibition.

ABSTRACT: Neprilysin (NEP) cleaves active forms of A- and B-type natriuretic peptides (ANP and BNP) at multiple sites, reducing their compensatory effects in heart failure. Therapeutic inhibition of NEP by sacubitrilat may potentiate the beneficial effects of natriuretic peptides. Neprilysin 2 (NEP2), a close homolog of NEP, has been described in humans but remains poorly characterized. This study aimed to investigate NEP2 expression in the cardiovascular system, its ability to cleave natriuretic peptides, and its inhibition by sacubitrilat. NEP and NEP2 expression profiles were assessed using reverse transcription PCR. The efficiency of in vitro cleavage of ANP, BNP, and the BNP precursor proBNP by NEP and NEP2 recombinant soluble domains was evaluated using sandwich-type immunoassays using antibod

SUBMITTER: Selezneva EM 

PROVIDER: S-EPMC12304097 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature